GSK, Novartis partner to support scientific research into genetic diversity in Africa
As part of commitment to aiding the health sector, two giant multinational pharmaceutical companies, GlaxoSmithKline (GSK) and Novartis International have announced a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.
The Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis.
Commenting on the new development, Senior Vice President Global Health Pharma at GSK, Pauline Williams said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having a varying response to treatments. We are excited to launch Project Africa GRADIENT which aims to catalyse the best science in the continent to optimize treatment responses for malaria and tuberculosis, two infectious diseases that disproportionately affect African populations.”
Also responding, M.D., Chief Operating Officer for Global Health at Novartis, Lutz Hegemann said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world. Our efforts include seeking innovative ways to improve the standard of care where possible.
“This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa. It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis.
“In alignment with our ongoing efforts to strengthen scientific capabilities in lower-resource settings, this project also provides opportunities for training young African scientists in the use of advanced research methodologies and mentoring on drug development.”
Project Africa GRADIENT comprises three funding mechanisms to support:
Fellowships: A limited number of fellowships in academic institutions with a reputation for global excellence to collect and analyse data on determinants of drug response.
Investigator-sponsored research: Hypothesis-driven research focused on understanding genetic regional variation in drug response.
Seed-Fund: A limited number of projects to enable the exploration of new research goals, depending on the results from 1 and 2.
Within the scope of the agreement, South African Medical Research Council (SAMRC) is said to administer the project, and a Joint Steering Committee will oversee the review of submitted proposals.
It was also said that Priority will be given to research aimed at collecting data from currently under-represented regions and improving the scientific robustness of inconsistent data. All datasets collated are planned to be released in a public database to catalyse a positive change in approach to understanding variations in treatment efficacy and safety for patients across the continent.
South African Medical Research Council (SAMRC) President and CEO, Glenda Gray expressed that:
“It is exciting to see more and more global partners taking interest in the challenges of Africa. We are delighted that partners are now seeking to address the challenges of Africa by their quest to understand the fundamental differences between the genetics of Africa and the rest of the world.”
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company with headquartered in Brentford, England; while Novartis International is a Swiss multinational pharmaceutical company based in Basel, Switzerland.
RECOMMENDED ARTICLES
Comment
No comments found.